We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Manchester Science Park’s acquisition of AstraZeneca’s Alderley Park site

Manchester Science Park

Manchester Science Parks (MSP) today closed a great year for the Bruntwood owned business, with a strong financial performance, the launch of plans to triple the size of its core Manchester campus and to acquire Alderley Park, AstraZaneca's flagship R&D site, in a deal which will catapult MSP to the forefront of commercial life sciences in the North of England.

An investment programme which included the refurbishment of The MedTech Centre, a medical technology hub incubator which is joint venture between Central Manchester University Hospitals NHS Foundation Trust, TRUSTECH and MSP that can hold up to 70 companies, has helped deliver a 91% occupancy level for MSP and impressive finance results for the year ending September 2013.

Further growth comes from today exchanging contracts on AstraZeneca's 400 acre site, Alderley Park, in Cheshire. The acquisition is funded by MSP, Bruntwood and Cheshire East Council, with Bruntwood as the majority funder.

MSP plans to build on Alderley Park's heritage of scientific innovation, retaining the assets and talent at the campus and repurposing it as a life science business cluster that establishes the North West as a driver of science sector growth for the UK.

Chris Oglesby, Chairman of MSP and Chief Executive of Bruntwood, said: "This is a truly unique opportunity to take on one of the best invested sites in the world, complete with state of the art facilities and equipment for bioscience companies.

"We are delighted to have been entrusted with securing the future of Alderley Park as a life science facility of world class scale and quality. We are committed to developing a sector-led business cluster of international importance on the site, making it a flagship location of its kind for the North of England and the UK."

Rowena Burns, Chief Executive, MSP, added: "Our overall strategy and vision is to bring together the strengths of Alderley Park, as a bioscience R&D facility of unique scale and quality, with the existing MSP clusters and links to the knowledge base to create an internationally compelling commercial science offer and driver of future economic growth.

"We're making huge strides in securing MSP's place as the driver of innovation in the city region and as an organisation that helps to bring great ideas to the world. Our work in growing the Corridor campus and securing the legacy of Alderley Park will significantly raise our presence and profile in the region and beyond."

Mike Deegan, the CMFT CEO said "The recent acquisition of Astra Zeneca's Alderley development by Manchester Science Park (MSP) is fantastic news for life science industry and healthcare innovation, not only in Manchester but for the UK. With more life sciences companies choosing to locate to Alderley Park, it will give CMFT and MSP opportunity to work in partnership with these companies to develop the new diagnostics and therapeutics that we need to drive innovation to improve patient care.

"CMFT is already working in partnership with MSP and Bruntwood through Citylabs, a £24m biomedical centre of excellence, located on the CMFT campus, which is due to open June 2014 and is currently 60% pre-let."